Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.53 |
| ▸ | DHFR | P00374 | 5/20 | 0.53 |
| ▸ | FOLR1 | P15328 | 5/20 | 0.53 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.53 |
| ▸ | SLC46A1 | Q96NT5 | 5/20 | 0.53 |
| ▸ | GART | P22102 | 5/20 | 0.53 |
| ▸ | ATIC | P31939 | 4/20 | 0.53 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.53 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.53 |
| ▸ | FRK | P42685 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423094 | 0.93 | TYMS (0.53) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL21706291 | 0.83 | TYMS (0.52) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL11990700 | 0.81 | TYMS (0.46) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL423888 | 0.81 | TYMS (0.46) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL464402 | 0.80 | GART (0.71) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL15145419 | 0.80 | GART (0.73) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL21558193 | 0.80 | GART (0.73) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL11990575 | 0.78 | TYMS (0.47) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL422998 | 0.78 | TYMS (0.42) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL11990724 | 0.78 | GART (0.70) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TYMS 655/4885DHFR 508/4885FOLR1 763/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TYMS 545/4885DHFR 494/4885FOLR1 347/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TYMS 545/4885DHFR 494/4885FOLR1 347/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | TYMS 2668/4885DHFR 1629/4885FOLR1 1271/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | TYMS 2668/4885DHFR 1629/4885FOLR1 1271/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TYMS 655/4885DHFR 508/4885FOLR1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.